Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 2 128 GBX -0.84% Market Closed
Market Cap: 4.7B GBX

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Hikma Pharmaceuticals PLC

Revenue
3.2B USD
Cost of Revenue
-1.7B USD
Gross Profit
1.4B USD
Operating Expenses
-819m USD
Operating Income
629m USD
Other Expenses
-270m USD
Net Income
359m USD

Margins Comparison
Hikma Pharmaceuticals PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.7B GBP
46%
20%
11%
US
Eli Lilly and Co
NYSE:LLY
776.5B USD
82%
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
377.9B USD
68%
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
84%
45%
35%
CH
Roche Holding AG
SIX:ROG
214.5B CHF
74%
33%
14%
CH
Novartis AG
SIX:NOVN
190.4B CHF
76%
33%
24%
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP
82%
24%
14%
US
Merck & Co Inc
NYSE:MRK
205.6B USD
78%
34%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
139.5B USD
75%
27%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Hikma Pharmaceuticals PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.7B GBP
16%
7%
19%
12%
US
Eli Lilly and Co
NYSE:LLY
776.5B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
377.9B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
214.5B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
190.4B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
205.6B USD
39%
16%
25%
19%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
139.5B USD
9%
4%
10%
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less